Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Olivia Vergnolle
Institution:
Tri-Institutional Therapeutics Discovery Institute
Observed institution:
Tri-Institutional Therapeutics Discovery Institute
ORCID:
0000-0001-6885-6145
Observed ORCID:
0000-0001-6885-6145
OpenAlex ID:
A5114385614
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
2025
·
Masataka Amisaki
, Abderezak Zebboudj
, et al.
·
Nature
·
149
PDF
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers
2026
·
Salomon Tendler
, Roberto De Gregorio
, et al.
·
Proceedings of the National Academy of Sciences
·
10
PDF
ROS‐Activatable Prodrug of Doxazolidine as Novel Cancer Therapy Paradigm
2024
·
Ryo Tamura
, Chace I. Carpenter
, et al.
·
Advanced Therapeutics
·
2
PDF
Abstract B079: Interleukin-33 activated ILC2s induce tertiary lymphoid structures in pancreatic cancer
2025
·
Abderezak Zebboudj
, Masataka Amisaki
, et al.
·
Cancer Immunology Research
Show more works
View as search
Works count:
4
Citation count:
161
H-index:
2
I10-index:
2
Year
Topic
Type
